½ÃÀ庸°í¼­
»óǰÄÚµå
1410941

ÁÖ¿ä 8°³±¹ÀÇ ÁÖ¿ä¿ì¿ïÀå¾Ö(MDD) Ä¡·áÁ¦ ¿¹Ãø ¹× ½ÃÀå ºÐ¼® - ÃֽŠÁ¤º¸

Major Depressive Disorder - Eight-Market Drug Forecast and Market Analysis - Update

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: GlobalData | ÆäÀÌÁö Á¤º¸: ¿µ¹® 117 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÁÖ¿ä¿ì¿ïÀå¾Ö(MDD)´Â ¼¼°è¿¡¼­ °¡Àå ÈçÇÑ Á¤½ÅÁúȯ Áß ÇϳªÀ̸ç, ´Ü¹ß¼º ¶Ç´Â ¹Ýº¹ÀûÀÎ ´ë¿ì¿ïÁõ ¿¡ÇǼҵå(MDE)¸¦ Ư¡À¸·Î ÇÕ´Ï´Ù. ¿ì¿ïÁõ ¿¡ÇǼҵå´Â °æÇèÇÑ Áõ»óÀÇ ¼ö¿Í ½É°¢µµ¿¡ µû¶ó °æÁõ, Áߵ ¶Ç´Â ÁßÁõÀ¸·Î ºÐ·ùµË´Ï´Ù. ¶ÇÇÑ, °¢ ÁßÁõµµÀÇ È¯ÀÚ Áß ÀϺδ ġ·á ÀúÇ×¼ºÀ¸·Î ºÐ·ùµÇ´Âµ¥, ÀÌ´Â ÀϹÝÀûÀ¸·Î ȯÀÚ°¡ ÃÖ¼Ò µÎ ¹øÀÇ Ç׿ì¿ïÁ¦ Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â °æ¿ì·Î, MDD´Â Àç¹ß¼º ÁúȯÀ̸ç, ¸¹Àº ȯÀڵ鿡°Ô ù ¹øÂ° ¿ì¿ïÁõ ¿¡ÇǼҵå´Â ½É¸®»çȸÀû ±â´É¿¡ ½É°¢ÇÑ Àå¾Ö¸¦ µ¿¹ÝÇÏ´Â Àç¹ß¼º, ¼è¾à¼º ¸¸¼º ÁúȯÀ¸·Î ¹ßÀüÇÕ´Ï´Ù. ÁúȯÀ¸·Î ¹ßÀüÇÕ´Ï´Ù.

MDDÀÇ °ü¸®¿¡´Â ȯÀÚ°¡ óÀ½ Ä¡·á¸¦ ¹ÞÀ» ¶§ºÎÅÍ ¿ì¿ïÁõ Áõ»óÀÌ ¿ÏÈ­µÉ ¶§±îÁöÀÇ ±Þ¼º ´Ü±â Ä¡·á¿Í ¿ÏÀüÇϰí Áö¼ÓÀûÀÎ ±â´ÉÀû ȸº¹À» ½ÃµµÇÏ´Â µ¿½Ã¿¡ Áõ»óÀÇ Àç¹ßÀ» ¹æÁöÇÏ´Â Àå±â À¯Áö ¿ä¹ýÀÌ Æ÷ÇԵ˴ϴÙ. Ç׿ì¿ïÁ¦ Ä¡·á¸¦ °­È­Çϱâ À§ÇØ Ãß°¡ÇÒ ¼ö ÀÖ´Â ´Ù¸¥ ¾à¹°µµ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä¿ì¿ïÀå¾Ö(MDD) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, Áúȯ °³¿ä, ¿ªÇÐ, Áúº´ °ü¸®, °æÀï Æò°¡, ¹ÌÃæÁ· ¼ö¿ä, R&D Àü·«, ÇöÀç ¹× ÇâÈÄ ÁøÃâ ±â¾÷, ½ÃÀå Àü¸Á µîÀÇ Á¤º¸¸¦ »ó¼¼ÇÏ°Ô Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä¿ì¿ïÀå¾Ö(MDD) : ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­·Ð

Á¦3Àå Áúȯ °³¿ä

Á¦4Àå ¿ªÇÐ

Á¦5Àå Áúº´ °ü¸®

Á¦6Àå °æÀï·Â Æò°¡

Á¦7Àå ¹ÌÃæÁ· ¿ä±¸¿Í ±âȸ Æò°¡

Á¦8Àå ¿¬±¸°³¹ß Àü·«

Á¦9Àå ÆÄÀÌÇÁ¶óÀÎ Æò°¡

Á¦10Àå ÆÄÀÌÇÁ¶óÀÎ Æò°¡ ºÐ¼®

Á¦11Àå ÇöÀç ¹× ÇâÈÄ Âü¿© ±â¾÷

Á¦12Àå ½ÃÀå Àü¸Á

Á¦13Àå ºÎ·Ï

LSH 24.01.30

Abstract

The report provides an in-depth assessment of the MDD market including disease overview, epidemiology, disease management, competitive assessment, unmet needs, R&D strategies, current and future players, and market outlook.

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide, and is characterized by single or recurrent major depressive episodes (MDEs). Episodes of depression can be classified as mild, moderate, or severe, based on the number and severity of symptoms experienced. In addition, a subset of patients in each severity can be classified as being treatment-resistant, typically when patients do not respond to at least two antidepressant treatments. MDD is a recurrent disorder, and for many patients, an initial episode of depression evolves into a recurrent and debilitating chronic illness with significant impairments in psychosocial functioning.

The management of MDD involves acute, short-term therapy from when patients are initially provided treatment until remission of their depressive symptoms, and long-term maintenance treatment aimed at preventing the recurrence of symptoms with an attempt to enable a full, lasting, and functional recovery. There is a wide range of antidepressants available to treat MDD, as well as a variety of other drugs that can be added on to boost treatment with antidepressants.

Key Highlights

  • Forecast includes the 8 major markets (8MM)
  • Forecast covers the period 2019-2029

Scope

  • Overview of major depressive disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized MDD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three adult patient segments (mild, moderate, and severe) from 2019 to 2029.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MDD therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the MS therapeutics market.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MDD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1. Major Depressive Disorder: Executive Summary - Updated Nov 2023, based on events up to Oct 31, 2023

2. Introduction - Updated Nov 2023, based on events up to Oct 31, 2023

3. Disease Overview - Updated Nov 2023, based on events up to Oct 31, 2023

4. Epidemiology

5. Disease Management - Updated Nov 2023, based on events up to Oct 31, 2023

6. Competitive Assessment - Updated Nov 2023, based on events up to Oct 31, 2023

7. Unmet Needs and Opportunity Assessment - Updated Nov 2023, based on events up to Oct 31, 2023

8. R&D Strategies - Updated Nov 2023, based on events up to Oct 31, 2023

9. Pipeline Assessment - Updated Nov 2023, based on events up to Oct 31, 2023

10. Pipeline Valuation Analysis - Updated Nov 2023, based on events up to Oct 31, 2023

11. Current and Future Players - Updated Nov 2023, based on events up to Oct 31, 2023

12. Market Outlook - Updated Nov 2023, based on events up to Oct 31, 2023

13. Appendix - Updated Apr 2023, based on events up to Apr 13, 2023

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦